Inify Laboratories: Gains traction in the UK - growing NHS interest and data confirming exceptional diagnostic quality

STOCKHOLM - October 28, 2026 - Inify Laboratories, a unique laboratory service that provides diagnostics within pathology, is now delivering its services to University Hospital Plymouth NHS Trust (UHP) on a regular basis. The agreement has attracted attention in the UK market and contributed to a clear increase in interest from hospitals across the country. At the same time, new data covering nearly 2,000 patient cases confirm the exceptional quality of Inify's diagnostics.

During the third quarter, the establishment team handed over operations to Inify's local laboratory team. Feedback from the diagnosticians at UHP working in Inify's system has been very positive, which lays the foundation for increasing Inify's share of the hospital's total sample volume, in line with the agreed evaluation plan.

"The agreement with UHP has drawn attention in the UK. It has advanced our existing dialogues and created new opportunities with hospitals in several regions. Most hospitals face significant challenges in meeting the requirements for effective pathways for patients investigated for prostate cancer, and our end-to-end solution is designed to solve exactly that - in close collaboration with each hospital," says Fredrik Palm, CEO of Inify.

Entering into evaluation agreements within the NHS is a complex process involving many stakeholders, as well as funding from regional organisations such as Cancer Alliances. After a successful evaluation, Inify's goal is to move on to a traditional procurement of the company's services.

Data confirm exceptional diagnostic quality

At the European pathology congress in Stockholm, Inify presented several research reports. In one of these, external pathologists reviewed nearly 2,000 patient cases previously diagnosed by Inify. Minor changes were made in only 3.6 percent of the cases, and none were considered to warrant a change to a possible treatment decision. In published studies, deviations on pathological follow-up have been reported in the range of 20-40 percent, although the extent and clinical significance vary.

"These results are extreme and testify to an exceptionally high diagnostic quality. For hospitals choosing a partner in pathology, documented quality is crucial," says Palm.

AI research with Karolinska Institute

As part of an ongoing research project with Karolinska Institute, data were presented where AI algorithms were used to study the relationship between a specific tumour growth pattern and patient outcomes in historical data. The results indicate that this growth pattern may be an important marker for aggressive disease.

"This is a typical example of how we can contribute to the development of cancer care. Identifying markers for aggressive disease can ultimately help clinicians make better treatment decisions for each patient," says Palm.

Saving two working weeks for urologists

A recent upgrade of Inify's in-house developed system added several new features, including support for clinicians' reporting to national cancer registries. This feature alone can save approximately ten minutes per patient for the urologist - equivalent to two full working weeks per year for a urologist handling 500 cancer patients annually.

"Healthcare faces a growing shortage of trained personnel, and our services are designed to meet exactly that challenge. We are driving a paradigm shift, which requires perseverance. My optimism about Inify's future grows stronger as we become increasingly established in the market," says Palm.

For further information, please contact CEO, Fredrik Palm, fredrik.palm@inify.com, or visit https://www.inify.com 

###

This information is subject to the disclosure requirements pursuant to section 5 -12 of the Norwegian Securities Trading Act.

###

The future of diagnostics

Inify Laboratories offers diagnostics through specialised laboratory services in histopathology, with a focus on streamlining patient pathways. The company performs clinical diagnostics in prostate cancer and gastroenterology, providing an integrated service that spans from early sample handling to final diagnosis.  The laboratory system is scalable both in handling large volumes of patient samples and for replicating in new locations.

Quality and response times are optimised in every step - from logistics to tissue preparation and diagnosis - using a fully digital, standardised and AI-assisted workflow. The diagnosis is always performed by a pathologist and is assisted by Inify's proprietary AI, proven to have world-leading precision in clinical evaluations. The entire workflow is supported by a tailor-made system that also enables development to include additional diagnostic areas.

Inify Laboratories is an international group headquartered in Solna, Sweden, with local laboratories in Sweden and the UK. The company's share is listed on Euronext Growth Oslo under the ticker INIFY.